Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_assertion type Assertion NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_head.
- NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_assertion description "[CYP2C19*2(G681A), CYP2C19*3(G636A), CYP2D6*4(C188T), CYP2D6*2(C2938T, G4268C), CYP3AP1*3- G44A and CYP3A5*3(A22893G) are the most common polymorphisms detected among Chinese that may influence the efficacy of vinorelbine-based therapies to treat non-small-cell lung cancer (NSCLC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_provenance.
- NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_assertion evidence source_evidence_literature NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_provenance.
- NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_assertion SIO_000772 17450472 NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_provenance.
- NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_assertion wasDerivedFrom befree-20140225 NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_provenance.
- NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_assertion wasGeneratedBy ECO_0000203 NP856731.RAlSk4FUO3evTXC8dUwM51jsEMqiUyDE3VsNQVK6TVp20130_provenance.